Acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative disorder (MPD)

26 cases of t(3;5)(q21;q31) in myeloid malignancy are available (Oshimura et al., 1976; Dewald, 1984; Bitter et al., 1985; Testa et al., 1985; Werner-Favre et al., 1985; Pi and Kalousek, 1986; Smadja et al., 1986; McCarthy et al., 1987; Sharp et al., 1987; Akiyoshi et al., 1991; Katz et al., 1992; Solé et al., 1992; Secker-Walker et al., 1995; Wong and Kwong, 1995; Groupe Français de Cytogénétique Hématologique, 1996; Dong et al., 1998; Mazzella et al., 1998; Misawa et al., 1998; Green et al., 1999; Berger et al., 2006; Lugthart et al., 2010). We have excluded from this review a case of acute lymphoblastic leukemia (Chen et al., 1992).

There was 5 M6-AMLs, 2 M4-AMLs, 10 M2-AMLs, and 6 AMLs not otherwise specified (AML-NOS), 1 myeloid metaplasia with myelofibrosis (MMM) in acute phase, another myeloproliferative syndrome not otherwise specified, and a refractory anemia with excess of blasts in transformation (RAEB-t). There was no reference with a previous toxic exposure.

Median age was 36-38 years (range 3-85, with two pediatric cases aged 3); sex ratio was 11M/14F.

Data on survival is very scarce (patients alive at 3 months, 21 months, 29 months, and 30 months; and patients dead at 7 and 9 months).